Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations?

Nahata, Leena; Woodruff, Teresa K.; Quinn, Gwendolyn P.; Meacham, Lillian R.; Chen, Diane; Appiah, Leslie; Finlayson, Courtney; Orwig, Kyle E.; Laronda, Monica M.; Rowell, Erin E.; Anazodo, Antoinette; Frias, Olivia; Rios, Julie Sroga; Whiteside, Stacy; Gómez-Lobo, Veronica; Dwiggins, Maggie; Childress, Krista J.; Hoefgen, Holly; Levine, Jennifer; Jayasinghe, Yasmin; Moravek, Molly B.

doi:10.1007/s10815-020-01794-7

Cited by 45 publications

(25 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, while OTC is no longer considered an experimental technique and has been proven to be successful, researchers have pointed to the invasiveness of the procedure (22) and advised the necessity for future research into OTC for young patients (23). Although OTC is currently the ''standard of care'' for prepubertal girls, it is imperative to continue fertility preservation research in the prepubertal population to open more possibilities in the future.…”

Section: Discussionmentioning

confidence: 99%

Case report: two cases of mature oocytes found in prepubertal girls during ovarian tissue cryopreservation

et al. 2021

Self Cite

View full text Add to dashboard Cite

Objective: To report two cases of mature oocytes found in prepubertal girls undergoing ovarian tissue cryopreservation (OTC). Design: Case report. Setting: Large tertiary care children's hospital and a private fertility clinic. Patient(s): An 8-year-old prepubertal girl with b-thalassemia and a 2-year-old girl with sickle cell disease who both underwent OTC before bone marrow transplantations. Intervention(s): Laparoscopic right oophorectomy was performed in each patient. The ovarian cortical tissue was processed for slow freezing and long-term storage, and all oocytes were subsequently vitrified. Main Outcome Measure(s): Oocytes found at the time of OTC processing for fertility preservation. Result(s): After a complete right oophorectomy, one mature metaphase II oocyte was discovered on tissue processing for OTC in each patient. Neither patient has yet returned for use of tissue or oocytes. Conclusion(s):To our knowledge, this is the first report of mature oocytes found during prepubertal OTC processing. These findings may indicate the need for increased research regarding prepubertal oocyte development and suggest that the technique of examining the media for both mature and immature oocytes at the time of OTC should become more widespread and perhaps recommended in prepubertal patients to optimize fertility preservation methods. (Fertil Steril Rep Ò 2021;2:296-9. Ó2021 by American Society for Reproductive Medicine.

show abstract

Section: Discussionmentioning

confidence: 99%

Case report: two cases of mature oocytes found in prepubertal girls during ovarian tissue cryopreservation

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The common forms of childhood cancers that may require aggressive gonadotoxic anticancer therapy and hence necessitate prior fertility preservation measures are leukemia, central nervous system cancers, lymphoma, and sarcomas. Unique medical challenges in oncofertility programs for childhood cancer exist and include the following: (1) freezing of gonadal tissues is the only suitable cryopreservation option before puberty, and (2) autotransplantation of frozen gonadal tissue may carry the risk of reintroducing malignant cells, especially in leukemia which is the most common childhood cancer [36][37][38][39][40][41][42].…”

Section: Installing Oncofertility Programs For Childhood Cancer In Opmentioning

confidence: 99%

Installing oncofertility programs for common cancers in optimum resource settings (Repro-Can-OPEN Study Part II): a committee opinion

2021

J Assist Reprod Genet

View full text Add to dashboard Cite

Purpose The main objective of Repro-Can-OPEN Study Part 2 is to learn more about oncofertility practices in optimum resource settings to provide a roadmap to establish oncofertility best practice models. Methods As an extrapolation for oncofertility best practice models in optimum resource settings, we surveyed 25 leading and wellresourced oncofertility centers and institutions from the USA, Europe, Australia, and Japan. The survey included questions on the availability and degree of utilization of fertility preservation options in case of childhood cancer, breast cancer, and blood cancer. Results All surveyed centers responded to all questions. Responses and their calculated oncofertility scores showed three major characteristics of oncofertility practice in optimum resource settings: (1) strong utilization of sperm freezing, egg freezing, embryo freezing, ovarian tissue freezing, gonadal shielding, and fractionation of chemo-and radiotherapy; (2) promising utilization of GnRH analogs, oophoropexy, testicular tissue freezing, and oocyte in vitro maturation (IVM); and (3) rare utilization of neoadjuvant cytoprotective pharmacotherapy, artificial ovary, in vitro spermatogenesis, and stem cell reproductive technology as they are still in preclinical or early clinical research settings. Proper technical and ethical concerns should be considered when offering advanced and experimental oncofertility options to patients. Conclusions Our Repro-Can-OPEN Study Part 2 proposed installing specific oncofertility programs for common cancers in optimum resource settings as an extrapolation for best practice models. This will provide efficient oncofertility edification and modeling to oncofertility teams and related healthcare providers around the globe and help them offer the best care possible to their patients.

show abstract

“…Recently, ASRM lifted the experimental label for OTC that can now be offered as a standard of care ( Medicine ECotASfR 2018 ). Traditionally in prepubertal females, OTC has been seen as the only option for fertility preservation which was generally completed under a research protocol ( Medicine ECotASfR 2018 , Nahata et al 2020 ). Currently, there is limited evidence regarding the safety and effectiveness of OTC in prepubertal patients with only one live birth as a result of OTC from a prepubertal patient ( Matthews et al 2018 ).…”

Section: Fertility Managementmentioning

confidence: 99%

Pathophysiology and management of classic galactosemic primary ovarian insufficiency

Hagen-Lillevik

Rushing

Appiah

et al. 2021

Reproduction and Fertility

View full text Add to dashboard Cite

Classic Galactosemia is an inborn error of carbohydrate metabolism associated with early-onset primary ovarian insufficiency (POI) in young women. Our understanding of the consequences of galactosemia upon fertility and fecundity of affected women is expanding, but there are important remaining gaps in our knowledge and tools for management, and a need for continued dialogue so that the special features of the condition can be better managed. Here, we review galactosemic POI and its reproductive endocrinological clinical sequelae and summarize current best clinical practices for its management. Special consideration is given to the very early-onset nature of the condition in the pediatric/adolescent patient. Afterward, we summarize our current understanding of the reproductive pathophysiology of galactosemia, including the potential action of toxic galactose metabolites upon the ovary. Our work establishing that ovarian cellular stress reminiscent of endoplasmic reticulum (ER) stress is present in a mouse model of galactosemia, as well as work by other groups, are summarized.

show abstract

Ovarian tissue cryopreservation as standard of care: what does this mean for pediatric populations?

Cited by 45 publications

References 18 publications

Case report: two cases of mature oocytes found in prepubertal girls during ovarian tissue cryopreservation

Case report: two cases of mature oocytes found in prepubertal girls during ovarian tissue cryopreservation

Installing oncofertility programs for common cancers in optimum resource settings (Repro-Can-OPEN Study Part II): a committee opinion

Pathophysiology and management of classic galactosemic primary ovarian insufficiency

Contact Info

Product

Resources

About